TAS6417 is a pan-Mutation Selective EGFR Inhibitor
Despite dramatic response to first and second-generation EGFR TKIs, resistance emerges over time. The EGFR-T790M mutation accounts for more than half of drug resistance. Third generation (covalent mutation-specific: osimertinib) EGFR…